Instil Bio(US:TIL)2025-05-13 11:05Financial Position - As of March 31, 2025, Instil Bio had total cash, cash equivalents, restricted cash, marketable securities, and long-term investments of $111.8 million, a decrease from $115.1 million as of December 31, 2024[3]. - Instil Bio's total assets decreased to $237.4 million as of March 31, 2025, from $263.6 million as of December 31, 2024[13]. - Instil Bio expects its current cash position to fund its operating plan beyond 2026[3]. Expenses - Research and development expenses for Q1 2025 were $5.4 million, down from $7.3 million in Q1 2024, representing a decrease of approximately 26%[4]. - General and administrative expenses decreased to $9.1 million in Q1 2025 from $12.4 million in Q1 2024, a reduction of about 27%[4]. - Restructuring and impairment charges increased significantly to $16.1 million in Q1 2025 from $4.3 million in Q1 2024, marking an increase of approximately 274%[4]. Net Loss - The net loss per share for Q1 2025 was $4.32, compared to $3.74 in Q1 2024, reflecting an increase of about 15%[6]. - Non-GAAP net loss per share for Q1 2025 was $1.32, down from $2.39 in Q1 2024, indicating an improvement of approximately 45%[6]. Clinical Trials - The ongoing Phase 1b/2 trial of AXN-2510/IMM2510 in combination with chemotherapy for 1L NSCLC in China is expected to provide initial clinical data in the second half of 2025[5]. - A U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy is anticipated to begin before the end of 2025, pending regulatory approvals[5].